NEW YORK (GenomeWeb) – Regeneron Pharmaceuticals said today that it has formed a pre-competitive consortium with AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, and Pfizer to sequence the exomes of all 500,000 participants in the UK Biobank.
"All of us involved have a shared belief in the power of genetics to facilitate and guide drug discovery and development," said Aris Baras, vice president and head of the Regeneron Genetics Center (RGC), a wholly-owned subsidiary of Regeneron.